NCT05513053: A reported trial by Sanofi Pasteur, a Sanofi Company
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05513053 |
|---|---|
| Title | Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 27, 2022 |
| Completion date | Oct. 27, 2023 |
| Required reporting date | Oct. 26, 2024, midnight |
| Actual reporting date | May 2, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |